SOURCE: Cannabis Therapy Corp.

Cannabis Therapy Corp.

May 19, 2014 08:00 ET

Cannabis Therapy Corp. Fox News Interview Today on "Opening Bell with Maria Bartiromo"

BOULDER, CO--(Marketwired - May 19, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"), a development stage enterprise focused on the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and therapeutically active component of cannabis, for the treatment of various conditions and diseases, is pleased to advise that Company President & CEO Soren Mogelsvang is scheduled to appear this morning on Fox Business News "Opening Bell with Maria Bartiromo."

The segment is slated to run during the regularly scheduled broadcast between 9 and 11 AM on Monday, May 19th. It is anticipated that interested viewers should be able to enjoy a repeat of the show at, later in the day.

For more information about the Company please visit and watch our corporate video at

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.


Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

Contact Information